Pub Date : 2023-07-11DOI: 10.37290/ctnr2641-452x.21:411-416
Lei Hu, Chenhao Zhang, Hailin Dai, Chunliang Zhang, Yuejun Yang, Nan Wang, Fengli Zhao
Transdermal patches of rotigotine, a dopamine agonist of the non-ergoline class, are used to treat the signs and symptoms of Parkinson’s disease. In this study, we have probed the effect of ginseng oral liquid on the efficacy of the rotigotin patch plus amantadine in treating Parkinson’s disease. Measurements of mental behavior, daily activities, and motor function were used to calculate the total effective rate of the treatment that was elevated in the presence of ginseng oral liquid. While ginseng oral liquid lowered the Parkinson’s Disease Questionnaire scores and levels of serum amyloid A and interleukin-12, it augmented apolipoprotein A1. No difference was seen in the incidence of adverse events between the two groups. To sum up, rotigotin patches in association with amantadine and ginseng oral liquid are effective in treating Parkinson’s disease, which can effectively promote the quality of life of patients, decrease clinical symptoms, and reduce inflammatory reactions.
罗替戈汀是一种非麦角林类多巴胺激动剂，其透皮贴片可用于治疗帕金森病的症状和体征。在这项研究中，我们探讨了人参口服液对罗替戈汀贴剂加金刚烷胺治疗帕金森病疗效的影响。通过对精神行为、日常活动和运动功能的测量，我们计算出了在人参口服液存在的情况下治疗总有效率的升高。虽然人参口服液降低了帕金森病问卷的得分以及血清淀粉样蛋白 A 和白细胞介素-12 的水平，但却增加了载脂蛋白 A1。两组的不良反应发生率没有差异。综上所述，罗替戈汀贴剂联合金刚烷胺和人参口服液治疗帕金森病疗效显著，可有效提高患者的生活质量，减轻临床症状，减少炎症反应。
{"title":"Ginseng Oral Liquid Enhances Therapeutic Output of Rotigotin Patch Plus Amantadine in Parkinson’s Disease","authors":"Lei Hu, Chenhao Zhang, Hailin Dai, Chunliang Zhang, Yuejun Yang, Nan Wang, Fengli Zhao","doi":"10.37290/ctnr2641-452x.21:411-416","DOIUrl":"https://doi.org/10.37290/ctnr2641-452x.21:411-416","url":null,"abstract":"Transdermal patches of rotigotine, a dopamine agonist of the non-ergoline class, are used to treat the signs and symptoms of Parkinson’s disease. In this study, we have probed the effect of ginseng oral liquid on the efficacy of the rotigotin patch plus amantadine in treating Parkinson’s disease. Measurements of mental behavior, daily activities, and motor function were used to calculate the total effective rate of the treatment that was elevated in the presence of ginseng oral liquid. While ginseng oral liquid lowered the Parkinson’s Disease Questionnaire scores and levels of serum amyloid A and interleukin-12, it augmented apolipoprotein A1. No difference was seen in the incidence of adverse events between the two groups. To sum up, rotigotin patches in association with amantadine and ginseng oral liquid are effective in treating Parkinson’s disease, which can effectively promote the quality of life of patients, decrease clinical symptoms, and reduce inflammatory reactions.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":"57 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139360377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-10DOI: 10.37290/ctnr2641-452x.21:490-494
Hui Shi, Shanshan Li
We have examined the influence of early postoperative nutritional nursing on the prognosis of patients undergoing gastrointestinal surgery. A total of 82 patients with gastrointestinal surgery were recruited from the First Affiliated Hospital of Soochow University between January 2020 and December 2022 for this study. The patients were divided into two equalsized control and treatment groups. The control group received routine care, whereas the treatment group received added nutritional care. Compared to the control group, the first exhaust time, first defecation time, and hospitalization time in the treatment group were shorter (P < 0.01). On the 7th day after surgery, no difference was found in the levels of albumin and total protein between the two groups (P > 0.05). However, on the 4th and 7th days after surgery, the diamine oxidase and malondialdehyde values in the treatment group were lower relative to the control group. Body weight in the treatment group was higher, the incidence of complications was lower, and the quality-of-life score and immune function were better compared to the control group (P < 0.05). To sum up, early nutritional care is beneficial to improving the immune function indexes, nutritional indexes, and quality of life of patients after gastrointestinal surgery, as well as reducing the occurrence of postoperative adverse reactions.
{"title":"Effect of Early Postoperative Nutritional Nursing on the Prognosis of Patients Undergoing Gastrointestinal Surgery","authors":"Hui Shi, Shanshan Li","doi":"10.37290/ctnr2641-452x.21:490-494","DOIUrl":"https://doi.org/10.37290/ctnr2641-452x.21:490-494","url":null,"abstract":"We have examined the influence of early postoperative nutritional nursing on the prognosis of patients undergoing gastrointestinal surgery. A total of 82 patients with gastrointestinal surgery were recruited from the First Affiliated Hospital of Soochow University between January 2020 and December 2022 for this study. The patients were divided into two equalsized control and treatment groups. The control group received routine care, whereas the treatment group received added nutritional care. Compared to the control group, the first exhaust time, first defecation time, and hospitalization time in the treatment group were shorter (P < 0.01). On the 7th day after surgery, no difference was found in the levels of albumin and total protein between the two groups (P > 0.05). However, on the 4th and 7th days after surgery, the diamine oxidase and malondialdehyde values in the treatment group were lower relative to the control group. Body weight in the treatment group was higher, the incidence of complications was lower, and the quality-of-life score and immune function were better compared to the control group (P < 0.05). To sum up, early nutritional care is beneficial to improving the immune function indexes, nutritional indexes, and quality of life of patients after gastrointestinal surgery, as well as reducing the occurrence of postoperative adverse reactions.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":"77 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139360675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-07DOI: 10.37290/ctnr2641-452x.21:222-227
Yan Sun, Yuxia Zhao, Yulong Liu, Zilang Yu, Fanrong Wu
Patients with coronary heart disease and angina pectoris were divided into two groups (control and treatment) of 54 patients per group. The control group received puerarin, whereas the treatment group received puerarin plus nicorandil. Therapeutic outcomes of two treatments were compared by assessing lower left ventricular end systolic diameter, lower left ventricular end diastolic diameter, higher left ventricular ejection fraction, duration of angina pectoris, number of angina attacks, dosage of nitroglycerin needed, plasma viscosity, whole blood viscosity, fibrinogen level, pro-inflammatory markers, as well as 36-item Short Form Survey scores. The total therapeutic rate was better in the group receiving both puerarin and nicorandil than puerarin alone. No difference was discovered in the incidence of adverse reactions between the two groups. This led us to conclude that puerarin combined with nicorandil is more effective in treating coronary heart disease and angina pectoris and can improve cardiac functions, lessen chemodynamic indexes and inflammatory reactions of angina pectoris, and promote the quality of life of patients.
{"title":"Puerarin Combined with Nicorandil is More Effective in Treating Coronary Heart Disease and Angina Pectoris","authors":"Yan Sun, Yuxia Zhao, Yulong Liu, Zilang Yu, Fanrong Wu","doi":"10.37290/ctnr2641-452x.21:222-227","DOIUrl":"https://doi.org/10.37290/ctnr2641-452x.21:222-227","url":null,"abstract":"Patients with coronary heart disease and angina pectoris were divided into two groups (control and treatment) of 54 patients per group. The control group received puerarin, whereas the treatment group received puerarin plus nicorandil. Therapeutic outcomes of two treatments were compared by assessing lower left ventricular end systolic diameter, lower left ventricular end diastolic diameter, higher left ventricular ejection fraction, duration of angina pectoris, number of angina attacks, dosage of nitroglycerin needed, plasma viscosity, whole blood viscosity, fibrinogen level, pro-inflammatory markers, as well as 36-item Short Form Survey scores. The total therapeutic rate was better in the group receiving both puerarin and nicorandil than puerarin alone. No difference was discovered in the incidence of adverse reactions between the two groups. This led us to conclude that puerarin combined with nicorandil is more effective in treating coronary heart disease and angina pectoris and can improve cardiac functions, lessen chemodynamic indexes and inflammatory reactions of angina pectoris, and promote the quality of life of patients.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":"148 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69758093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-07DOI: 10.37290/ctnr2641-452x.21:242-247
T. Matsuo, C. Yokoyama, Takako Yamada, T. Iida, S. Mochizuki, A. Yoshihara, K. Akimitsu
Medium-chain triglycerides, lipids containing three 6−12 carbon medium-chain fatty acids, have antiobesity effects because they do not promote lipogenesis. d-Allulose, a low-calorie epimer of fructose commercially used as a low-calorie sweetener, suppresses hepatic lipogenesis and enhances postprandial fat oxidation. Therefore, we have explored whether a simultaneous intake of medium-chain fatty acids and d-allulose may exhibit a greater reduction in de novo lipogenesis and increase their antiobesity effects. To this end, 32 male Wistar rats were divided into four treatment groups of equal sizes: control, 3% d-allulose-treated, 5% medium-chain triglycerides-treated, and 3% d-allulose + 5% medium-chain triglycerides-treated. After 8 weeks of ad libitum exposure to these diets, d-allulose significantly decreased intra-abdominal adipose tissue and total body fat weight, with or without medium-chain triglyceride supplementation. The antiobesity effect of d-allulose was observed with or without dietary medium-chain triglyceride supplementation in high-fat diet-induced obese rats, but no synergistic effect was detected between d-allulose and medium-chain triglycerides.
{"title":"Effect of Simultaneous Intake of Medium-Chain Triglyceride and d-Allulose on Body Fat Accumulation in Rats Fed a High-Fat Diet","authors":"T. Matsuo, C. Yokoyama, Takako Yamada, T. Iida, S. Mochizuki, A. Yoshihara, K. Akimitsu","doi":"10.37290/ctnr2641-452x.21:242-247","DOIUrl":"https://doi.org/10.37290/ctnr2641-452x.21:242-247","url":null,"abstract":"Medium-chain triglycerides, lipids containing three 6−12 carbon medium-chain fatty acids, have antiobesity effects because they do not promote lipogenesis. d-Allulose, a low-calorie epimer of fructose commercially used as a low-calorie sweetener, suppresses hepatic lipogenesis and enhances postprandial fat oxidation. Therefore, we have explored whether a simultaneous intake of medium-chain fatty acids and d-allulose may exhibit a greater reduction in de novo lipogenesis and increase their antiobesity effects. To this end, 32 male Wistar rats were divided into four treatment groups of equal sizes: control, 3% d-allulose-treated, 5% medium-chain triglycerides-treated, and 3% d-allulose + 5% medium-chain triglycerides-treated. After 8 weeks of ad libitum exposure to these diets, d-allulose significantly decreased intra-abdominal adipose tissue and total body fat weight, with or without medium-chain triglyceride supplementation. The antiobesity effect of d-allulose was observed with or without dietary medium-chain triglyceride supplementation in high-fat diet-induced obese rats, but no synergistic effect was detected between d-allulose and medium-chain triglycerides.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":"1 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69758107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-07DOI: 10.37290/ctnr2641-452x.21:215-221
Xiang-qin Wen, Xiaojin Yang
Amarogentin, a secoiridoid glycoside isolated from the Indian medicinal plant Swertia chirata, is widely known for its antileishmanial, antioxidative, hypoglycemic, antihepatotoxic, antimalarial, anti-inflammatory, and antimicrobial activities. It has been evaluated for its possible anticancerous role in lung cancer using A549 and H1299 cells as models. The results of these studies show a dose-dependent decrease in cell proliferation, cell migration, and invasion by amarogentin. Furthermore, amarogentin repressed stemness in lung cancer, as shown by a diminution in the expression of DLL4, NICD, and Hes1 proteins. In conclusion, we report for the first time the potential regulatory impact of amarogentin on lung cancer. These findings reveal that amarogentin treatment inhibits tumor stem cell-like features in lung cancer by regulating Notch signaling. Therefore, amarogentin may be deemed as a useful therapeutic drug for lung cancer.
{"title":"Amarogentin Inhibits Tumor Stem Cell-Like Features of Lung Cancer by Regulating Notch Signaling","authors":"Xiang-qin Wen, Xiaojin Yang","doi":"10.37290/ctnr2641-452x.21:215-221","DOIUrl":"https://doi.org/10.37290/ctnr2641-452x.21:215-221","url":null,"abstract":"Amarogentin, a secoiridoid glycoside isolated from the Indian medicinal plant Swertia chirata, is widely known for its antileishmanial, antioxidative, hypoglycemic, antihepatotoxic, antimalarial, anti-inflammatory, and antimicrobial activities. It has been evaluated for its possible anticancerous role in lung cancer using A549 and H1299 cells as models. The results of these studies show a dose-dependent decrease in cell proliferation, cell migration, and invasion by amarogentin. Furthermore, amarogentin repressed stemness in lung cancer, as shown by a diminution in the expression of DLL4, NICD, and Hes1 proteins. In conclusion, we report for the first time the potential regulatory impact of amarogentin on lung cancer. These findings reveal that amarogentin treatment inhibits tumor stem cell-like features in lung cancer by regulating Notch signaling. Therefore, amarogentin may be deemed as a useful therapeutic drug for lung cancer.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47964933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-07DOI: 10.37290/ctnr2641-452x.21:235-241
D. Korovljev, Dejan Javorac, N. Todorovic, Marijana Ranisavljev, D. Engeset, Tonje Holte Stea, J. Ostojić, Katarina Bijelić, Branislava Srdjenović Čonić, N. Kladar, L. Rátgéber, Nenad Trunić, Sava Rajkovic, V. Štajer, S. Ostojić
The aim of this randomized controlled trial was to analyze the effects of medium-term supplementation with hydrogen-rich water on brain metabolism, appetite-regulating hormones, body composition, and safety biomarkers in overweight adults. Twenty (n = 20, 10 females) apparently healthy adults with a body mass index >24.9 kg/m2 were assigned to receive 0.5 L per day of hydrogen-rich water (7.5 mg of hydrogen) or hydrogen-free water (tap water) for 12 weeks. Two-way analysis of variance with repeated measures revealed a significant difference between the two interventions in several body composition indices (P ≤ 0.05), with hydrogen-rich water superior to placebo to reduce waist circumference and mid-upper arm circumference by 1.31 cm (95% confidence interval, from –0.23 to 2.85) and 0.65 cm (95% confidence interval, from –0.10 to 1.40), respectively. Hydrogen-rich water outcompeted placebo to raise serum ghrelin levels, as the mean difference from the placebo group was 17.28 pmol/L (95% confidence interval, from 1.81 to 32.75) (P = 0.02). A non-significant strong positive trend (P = 0.10) was reported toward hydrogen-rich water being superior to placebo in augmenting total serum short-chain fatty acid levels, with a mean difference from the control group of 195.6 μmol/L (95% confidence interval, from –64.55 to 275.85). The mean fecal calprotectin levels were significantly reduced after hydrogen-rich water intervention for 19.7 μg/mg (95% confidence interval, from 0.31 to 39.09) (P = 0.03). Our findings advance hydrogen-rich water as a promising metabolic intervention in overweight adults, but further validation via multicentric longitudinal randomized controlled trials in metabolic and nutritional disorders is required.
{"title":"The Effects of 12-Week Hydrogen-Rich Water Intake on Body Composition, Short-Chain Fatty Acids Turnover, and Brain Metabolism in Overweight Adults: A Randomized Controlled Trial","authors":"D. Korovljev, Dejan Javorac, N. Todorovic, Marijana Ranisavljev, D. Engeset, Tonje Holte Stea, J. Ostojić, Katarina Bijelić, Branislava Srdjenović Čonić, N. Kladar, L. Rátgéber, Nenad Trunić, Sava Rajkovic, V. Štajer, S. Ostojić","doi":"10.37290/ctnr2641-452x.21:235-241","DOIUrl":"https://doi.org/10.37290/ctnr2641-452x.21:235-241","url":null,"abstract":"The aim of this randomized controlled trial was to analyze the effects of medium-term supplementation with hydrogen-rich water on brain metabolism, appetite-regulating hormones, body composition, and safety biomarkers in overweight adults. Twenty (n = 20, 10 females) apparently healthy adults with a body mass index >24.9 kg/m2 were assigned to receive 0.5 L per day of hydrogen-rich water (7.5 mg of hydrogen) or hydrogen-free water (tap water) for 12 weeks. Two-way analysis of variance with repeated measures revealed a significant difference between the two interventions in several body composition indices (P ≤ 0.05), with hydrogen-rich water superior to placebo to reduce waist circumference and mid-upper arm circumference by 1.31 cm (95% confidence interval, from –0.23 to 2.85) and 0.65 cm (95% confidence interval, from –0.10 to 1.40), respectively. Hydrogen-rich water outcompeted placebo to raise serum ghrelin levels, as the mean difference from the placebo group was 17.28 pmol/L (95% confidence interval, from 1.81 to 32.75) (P = 0.02). A non-significant strong positive trend (P = 0.10) was reported toward hydrogen-rich water being superior to placebo in augmenting total serum short-chain fatty acid levels, with a mean difference from the control group of 195.6 μmol/L (95% confidence interval, from –64.55 to 275.85). The mean fecal calprotectin levels were significantly reduced after hydrogen-rich water intervention for 19.7 μg/mg (95% confidence interval, from 0.31 to 39.09) (P = 0.03). Our findings advance hydrogen-rich water as a promising metabolic intervention in overweight adults, but further validation via multicentric longitudinal randomized controlled trials in metabolic and nutritional disorders is required.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48793610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study was designed to evaluate the effect of Bifidobacterium triple viable granules combined with montmorillonite powder in children with diarrhea. To this end, 60 children with diarrhea were divided into two groups of equal size, with one receiving montmorillonite powder alone (control) and the other receiving montmorillonite powder plus Bifidobacterium triple viable granules (treatment). The children in the treatment group experienced significantly higher overall relief from diarrhea that was associated with shorter durations of fever, diarrhea, abdominal pain, and vomiting, as well as shorter recovery times for stool characters and stool frequency. Also, the serum levels of C-reactive protein, Interleukin-4, and Interleukin-6 were lower, while Immunoglobulin A, Immunoglobulin G, and Immunoglobulin M levels were higher in the treatment group than the control group (P < 0.05). There were far fewer adverse reactions in the treatment group than in the control group. In summary, Bifidobacterium triple viable granules combined with montmorillonite powder are clinically superior in treating children with diarrhea.
{"title":"Bifidobacterium Triple Viable Granules Combined with Montmorillonite Powder in the Therapy of Children with Diarrhea","authors":"Wendi Jin, Er-te Yu, Yunbing Lu, Zhaolin Wang, Li Huang, X. Qiao","doi":"10.37290/ctnr2641-452x.21:272-276","DOIUrl":"https://doi.org/10.37290/ctnr2641-452x.21:272-276","url":null,"abstract":"This study was designed to evaluate the effect of Bifidobacterium triple viable granules combined with montmorillonite powder in children with diarrhea. To this end, 60 children with diarrhea were divided into two groups of equal size, with one receiving montmorillonite powder alone (control) and the other receiving montmorillonite powder plus Bifidobacterium triple viable granules (treatment). The children in the treatment group experienced significantly higher overall relief from diarrhea that was associated with shorter durations of fever, diarrhea, abdominal pain, and vomiting, as well as shorter recovery times for stool characters and stool frequency. Also, the serum levels of C-reactive protein, Interleukin-4, and Interleukin-6 were lower, while Immunoglobulin A, Immunoglobulin G, and Immunoglobulin M levels were higher in the treatment group than the control group (P < 0.05). There were far fewer adverse reactions in the treatment group than in the control group. In summary, Bifidobacterium triple viable granules combined with montmorillonite powder are clinically superior in treating children with diarrhea.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42403007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-07DOI: 10.37290/ctnr2641-452x.21:283-290
S. Alqahtani
Thyroid dysfunction is the most prevalent endocrine disorder worldwide. Thyroid hormone has a crucial role in maintaining a wide array of metabolic homeostasis. In addition to calcium and bone metabolism, vitamin D influences nonskeletal activities, including the thyroid gland. Therefore, hypovitaminosis D is considered a risk factor for the emergence of many thyroid dysfunctions. In this investigation, we aimed to investigate the association of vitamin D and serum calcium levels with thyroid dysfunction. In this investigation, 2,735 (1,438 females and 1,297 males) laboratory findings from the public, government hospital laboratories, and medical clinics serving chronic patients in the south region (Asir region) of Saudi Arabia were screened over the course of one year. The vitamin D level was significantly lower in both female and male patients in the hypothyroidism category than in the hyperthyroidism and euthyroidism groups. The influence of total serum calcium level was not significant in any thyroid dysfunction category. A high prevalence of normal levels of total serum calcium was observed in all thyroid status groups. A partial correlation between total serum calcium and vitamin D and TSH among thyroid dysfunction patients demonstrated a significant negative correlation between vitamin D and TSH and a nonsignificant negative correlation between total serum calcium level and TSH among hypothyroidism categories. However, in the hypothyroidism group, total serum calcium demonstrated a negative correlation with TSH, while vitamin D showed a positive correlation with TSH.
{"title":"Association of Vitamin D and Calcium Levels with Thyroid Status in the Southern Region of Saudi Arabia","authors":"S. Alqahtani","doi":"10.37290/ctnr2641-452x.21:283-290","DOIUrl":"https://doi.org/10.37290/ctnr2641-452x.21:283-290","url":null,"abstract":"Thyroid dysfunction is the most prevalent endocrine disorder worldwide. Thyroid hormone has a crucial role in maintaining a wide array of metabolic homeostasis. In addition to calcium and bone metabolism, vitamin D influences nonskeletal activities, including the thyroid gland. Therefore, hypovitaminosis D is considered a risk factor for the emergence of many thyroid dysfunctions. In this investigation, we aimed to investigate the association of vitamin D and serum calcium levels with thyroid dysfunction. In this investigation, 2,735 (1,438 females and 1,297 males) laboratory findings from the public, government hospital laboratories, and medical clinics serving chronic patients in the south region (Asir region) of Saudi Arabia were screened over the course of one year. The vitamin D level was significantly lower in both female and male patients in the hypothyroidism category than in the hyperthyroidism and euthyroidism groups. The influence of total serum calcium level was not significant in any thyroid dysfunction category. A high prevalence of normal levels of total serum calcium was observed in all thyroid status groups. A partial correlation between total serum calcium and vitamin D and TSH among thyroid dysfunction patients demonstrated a significant negative correlation between vitamin D and TSH and a nonsignificant negative correlation between total serum calcium level and TSH among hypothyroidism categories. However, in the hypothyroidism group, total serum calcium demonstrated a negative correlation with TSH, while vitamin D showed a positive correlation with TSH.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44810357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-07DOI: 10.37290/ctnr2641-452x.21:248-253
Yanchun Cao, Yunyun He
This study aimed to analyze the therapeutic effect of thunder-fire moxibustion plus Shenghua Decoction on uterine involution after cesarean section and its influence on lactation. One hundred and twenty parturients with post-cesarean section uterine involution were recruited from our hospital between October 2021 to July 2022. Participants were grouped into A, B, C, and D groups and treated with conventional therapy, Shenghua Decoction, thunder-fire moxibustion, and Shenghua Decoction+thunder-fire moxibustion, respectively. Groups B, C and D, especially group D, had shorter duration of lochia and faster descending speed of uterine fundus height than group A. All the four groups showed decreased uterine cavity volume after treatment, with the lowest volume found in group D. In terms of clinical efficacy, group D also had better treatment outcomes than the other three groups. Furthermore, the breast fullness degree and lactation yield scores were higher in group D than other groups, whilst the four groups were not statistically different in the incidence of adverse reactions. Shorter length of maternal hospital stays, and uterus recovery time were found in group D. In summary, thunder-fire moxibustion plus Shenghua Decoction should be treatment of choice for post-cesarean section uterine involution that can promote maternal breast milk secretion.
{"title":"A Combination of Thunder-Fire Moxibustion and Shenghua Decoction Enhances Uterine Involution After Cesarean Section and Postpartum Lactation","authors":"Yanchun Cao, Yunyun He","doi":"10.37290/ctnr2641-452x.21:248-253","DOIUrl":"https://doi.org/10.37290/ctnr2641-452x.21:248-253","url":null,"abstract":"This study aimed to analyze the therapeutic effect of thunder-fire moxibustion plus Shenghua Decoction on uterine involution after cesarean section and its influence on lactation. One hundred and twenty parturients with post-cesarean section uterine involution were recruited from our hospital between October 2021 to July 2022. Participants were grouped into A, B, C, and D groups and treated with conventional therapy, Shenghua Decoction, thunder-fire moxibustion, and Shenghua Decoction+thunder-fire moxibustion, respectively. Groups B, C and D, especially group D, had shorter duration of lochia and faster descending speed of uterine fundus height than group A. All the four groups showed decreased uterine cavity volume after treatment, with the lowest volume found in group D. In terms of clinical efficacy, group D also had better treatment outcomes than the other three groups. Furthermore, the breast fullness degree and lactation yield scores were higher in group D than other groups, whilst the four groups were not statistically different in the incidence of adverse reactions. Shorter length of maternal hospital stays, and uterus recovery time were found in group D. In summary, thunder-fire moxibustion plus Shenghua Decoction should be treatment of choice for post-cesarean section uterine involution that can promote maternal breast milk secretion.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46221157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-07DOI: 10.37290/ctnr2641-452x.21:208-214
Yao Liu, Qi-De Song, Ye Tian
Anacardic acid is a natural active ingredient that possesses diverse biological and pharmacological activities, such as being an antioxidant and cardioprotective agent that inhibits histone acetylation. This study aimed to evaluate the effect of anacardic acid on myocardial ischemia-reperfusion injury. The results of our studies show a significant inhibition of apoptosis and oxidative stress in H/R-treated H9C2 cells. Our results further reveal that the cardioprotective effect of anacardic acid was dependent on the inhibition of the NF-κB pathway. All these data taken together show anacardic acid as a potential therapeutic target in acute myocardial infarction.
{"title":"Anacardic Acid Alleviates Hypoxia/ReoxygenationInduced Injury in Cardiomyocytes via Suppressing Nuclear Factor-Kappa B Pathway","authors":"Yao Liu, Qi-De Song, Ye Tian","doi":"10.37290/ctnr2641-452x.21:208-214","DOIUrl":"https://doi.org/10.37290/ctnr2641-452x.21:208-214","url":null,"abstract":"Anacardic acid is a natural active ingredient that possesses diverse biological and pharmacological activities, such as being an antioxidant and cardioprotective agent that inhibits histone acetylation. This study aimed to evaluate the effect of anacardic acid on myocardial ischemia-reperfusion injury. The results of our studies show a significant inhibition of apoptosis and oxidative stress in H/R-treated H9C2 cells. Our results further reveal that the cardioprotective effect of anacardic acid was dependent on the inhibition of the NF-κB pathway. All these data taken together show anacardic acid as a potential therapeutic target in acute myocardial infarction.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47797648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：